Despite representing a significant area of unmet medical need, the inner ear remains one of the least innovated therapeutic spaces in medicine. Spiral is well positioned to address this disparity through precision delivery technologies capable of unlocking new treatment paradigms across multiple otologic indications.
Spiral Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for inner ear disorders, including hearing loss and balance disorders. Spiral’s MICS™ (Minimally-Invasive Cochlear System) drug delivery platform is designed to enable minimally invasive, precise and durable exposure of therapeutics to the cochlea. The company is advancing a pipeline of programs intended to address significant unmet needs across inner ear diseases.
Spiral is advancing a pipeline of programs targeting diseases of the inner ear. Its lead program, SPT-2101, delivered a statistically significant reduction of overall vertigo in patients with Ménière’s disease, and the company is preparing for a registrational clinical trial. Spiral’s MICS™ (Minimally-Invasive Cochlear System) drug delivery platform underpins a broader portfolio of hearing loss programs, including neurotrophic approaches designed to target fundamental disease pathobiology.
Read the full press release here.
